RUBY Profile
Rubius Therapeutics Inc. (RUBY) is a clinical-stage biopharmaceutical company that develops medicines using Red Cell Therapeutics (RCTs), a proprietary technology platform that creates innovative therapies that treat rare diseases, cancer, and autoimmune diseases. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Rubius Therapeutics is focused on developing a new class of medicines that harness the unique properties of red blood cells to create therapies that have the potential to transform the treatment of diseases. The company's RCT platform enables the production of therapeutic proteins and antibodies within red blood cells, which can be used to treat a wide range of diseases.
The company's lead product candidate, RTX-240, is a Red Cell Therapeutic that is currently being evaluated in a Phase 1/2 clinical trial for the treatment of solid tumors. The company is also developing a pipeline of Red Cell Therapeutics for the treatment of rare diseases, cancer, and autoimmune diseases.
Rubius Therapeutics is led by a team of experienced executives and scientists who are dedicated to advancing the company's mission of creating innovative therapies that improve the lives of patients. The company has partnerships with several leading biopharmaceutical companies and research institutions, and is well-funded to support its ongoing research and development efforts.
As of February 18, 2023, Rubius Therapeutics Inc.'s market capitalization was approximately $774 million, and the company's stock traded on the NASDAQ under the ticker symbol "RUBY".
|
